BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: af Björkesten CG, Nieminen U, Turunen U, Arkkila PE, Sipponen T, Färkkilä MA. Endoscopic monitoring of infliximab therapy in Crohn's disease. Inflamm Bowel Dis 2011;17:947-53. [PMID: 20860048 DOI: 10.1002/ibd.21439] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.2] [Reference Citation Analysis]
Number Citing Articles
1 af Björkesten C, Nieminen U, Sipponen T, Turunen U, Arkkila P, Färkkilä M. Mucosal healing at 3 months predicts long-term endoscopic remission in anti-TNF-treated luminal Crohn's disease. Scandinavian Journal of Gastroenterology 2013;48:543-51. [DOI: 10.3109/00365521.2013.772230] [Cited by in Crossref: 46] [Cited by in F6Publishing: 48] [Article Influence: 5.8] [Reference Citation Analysis]
2 Molander P, af Björkesten CG, Mustonen H, Haapamäki J, Vauhkonen M, Kolho KL, Färkkilä M, Sipponen T. Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNFα blocking agents. Inflamm Bowel Dis. 2012;18:2011-2017. [PMID: 22223566 DOI: 10.1002/ibd.22863] [Cited by in Crossref: 119] [Cited by in F6Publishing: 114] [Article Influence: 13.2] [Reference Citation Analysis]
3 Mazzuoli S, Guglielmi FW, Antonelli E, Salemme M, Bassotti G, Villanacci V. Definition and evaluation of mucosal healing in clinical practice. Dig Liver Dis. 2013;45:969-977. [PMID: 23932331 DOI: 10.1016/j.dld.2013.06.010] [Cited by in Crossref: 73] [Cited by in F6Publishing: 58] [Article Influence: 9.1] [Reference Citation Analysis]
4 Chan G, Fefferman DS, Farrell RJ. Endoscopic assessment of inflammatory bowel disease: colonoscopy/esophagogastroduodenoscopy. Gastroenterol Clin North Am 2012;41:271-90. [PMID: 22500517 DOI: 10.1016/j.gtc.2012.01.014] [Cited by in Crossref: 18] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
5 Feng T, Chen B, Ungar B, Qiu Y, Zhang S, He J, Lin S, He Y, Zeng Z, Ben-Horin S, Chen M, Mao R. Association of Infliximab Levels With Mucosal Healing Is Time-Dependent in Crohn's Disease: Higher Drug Exposure Is Required Postinduction Than During Maintenance Treatment. Inflamm Bowel Dis. 2019;25:1813-1821. [PMID: 30934050 DOI: 10.1093/ibd/izz061] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
6 Beppu T, Ono Y, Matsui T, Hirai F, Yano Y, Takatsu N, Ninomiya K, Tsurumi K, Sato Y, Takahashi H, Ookado Y, Koga A, Kinjo K, Nagahama T, Hisabe T, Takaki Y, Yao K. Mucosal healing of ileal lesions is associated with long-term clinical remission after infliximab maintenance treatment in patients with Crohn's disease: Ileal mucosal healing by IFX in CD. Digestive Endoscopy 2015;27:73-81. [DOI: 10.1111/den.12313] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
7 Imaeda H, Bamba S, Takahashi K, Fujimoto T, Ban H, Tsujikawa T, Sasaki M, Fujiyama Y, Andoh A. Relationship between serum infliximab trough levels and endoscopic activities in patients with Crohn's disease under scheduled maintenance treatment. J Gastroenterol. 2014;49:674-682. [PMID: 23666424 DOI: 10.1007/s00535-013-0829-7] [Cited by in Crossref: 74] [Cited by in F6Publishing: 71] [Article Influence: 9.3] [Reference Citation Analysis]
8 Shen W, Cao L, Li Y, Cai X, Ge Y, Zhu W. Visceral Fat Is Associated With Mucosal Healing of Infliximab Treatment in Crohn’s Disease. Diseases of the Colon & Rectum 2018;61:706-12. [DOI: 10.1097/dcr.0000000000001074] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
9 Inflammatory Bowel Disease Group, Chinese Society of Gastroenterology, Chinese Medical Association. Chinese consensus on diagnosis and treatment in inflammatory bowel disease (2018, Beijing). J Dig Dis 2021;22:298-317. [PMID: 33905603 DOI: 10.1111/1751-2980.12994] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Argollo M, Kotze PG, Kakkadasam P, D'Haens G. Optimizing biologic therapy in IBD: how essential is therapeutic drug monitoring? Nat Rev Gastroenterol Hepatol 2020;17:702-10. [PMID: 32879465 DOI: 10.1038/s41575-020-0352-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 10.0] [Reference Citation Analysis]
11 Lopetuso LR, Gerardi V, Papa V, Scaldaferri F, Rapaccini GL, Gasbarrini A, Papa A. Can We Predict the Efficacy of Anti-TNF-α Agents? Int J Mol Sci 2017;18:E1973. [PMID: 28906475 DOI: 10.3390/ijms18091973] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 10.8] [Reference Citation Analysis]
12 Beigel F, Deml M, Schnitzler F, Breiteneicher S, Göke B, Ochsenkühn T, Brand S. Rate and predictors of mucosal healing in patients with inflammatory bowel disease treated with anti-TNF-alpha antibodies. PLoS One 2014;9:e99293. [PMID: 24932476 DOI: 10.1371/journal.pone.0099293] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
13 Jongsma MME, Aardoom MA, Cozijnsen MA, van Pieterson M, de Meij T, Groeneweg M, Norbruis OF, Wolters VM, van Wering HM, Hojsak I, Kolho KL, Hummel T, Stapelbroek J, van der Feen C, van Rheenen PF, van Wijk MP, Teklenburg-Roord STA, Schreurs MWJ, Rizopoulos D, Doukas M, Escher JC, Samsom JN, de Ridder L. First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn's disease: an open-label multicentre randomised controlled trial. Gut 2020:gutjnl-2020-322339. [PMID: 33384335 DOI: 10.1136/gutjnl-2020-322339] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
14 Ananthakrishnan AN, Korzenik JR, Hur C. Can mucosal healing be a cost-effective endpoint for biologic therapy in Crohn's disease? A decision analysis. Inflamm Bowel Dis. 2013;19:37-44. [PMID: 22416019 DOI: 10.1002/ibd.22951] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 4.1] [Reference Citation Analysis]
15 De Cruz P, Kamm MA, Prideaux L, Allen PB, Moore G. Mucosal Healing in Crohnʼs Disease: A Systematic Review. Inflammatory Bowel Diseases 2013;19:429-44. [DOI: 10.1002/ibd.22977] [Cited by in Crossref: 101] [Cited by in F6Publishing: 88] [Article Influence: 12.6] [Reference Citation Analysis]
16 Cazzato G, Colagrande A, Andriola V, Lettini T, Cicco S, Candance PMV, Resta L, Vincenti L, Ingravallo G. Histological Hallmarks of Mucosal Healing in Inflammatory Bowel Diseases in the Era of Monoclonal Antibodies Therapy: New Insights and Perspectives. Diagnostics (Basel) 2021;11:1570. [PMID: 34573912 DOI: 10.3390/diagnostics11091570] [Reference Citation Analysis]
17 Qiu Y, Chen BL, Mao R, Zhang SH, He Y, Zeng ZR, Chen MH. Endoscopy Assessment at 1-Year Identifies Long-Term Responders to Thiopurines Maintenance Therapy in Patients With Crohn's Disease. Medicine (Baltimore) 2015;94:e1204. [PMID: 26252278 DOI: 10.1097/MD.0000000000001204] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
18 Hao X, Feng T, Yang Y, Shi Y, Jing R, Liu S, Luo Y, Qiao Y, Zhong M, Yu M. Laparoscopic bowel resection combined with infliximab treatment (LaRIC) versus infliximab for terminal ileitis in Crohn's disease: a randomised, controlled, open-label trial. BMJ Open 2020;10:e038429. [PMID: 33199421 DOI: 10.1136/bmjopen-2020-038429] [Reference Citation Analysis]
19 Reinink AR, Lee TC, Higgins PD. Endoscopic mucosal healing predicts favorable clinical outcomes in inflammatory bowel disease: A meta-analysis. Inflamm Bowel Dis. 2016;22:1859-1869. [PMID: 27206015 DOI: 10.1097/mib.0000000000000816] [Cited by in Crossref: 61] [Cited by in F6Publishing: 23] [Article Influence: 20.3] [Reference Citation Analysis]
20 Mao R, Qiu Y, Chen BL, Zhang SH, Feng R, He Y, Zeng ZR, Ben-Horin S, Chen MH. Factors associated with the achievement of mucosal healing in Crohn's disease: the benefit of endoscopic monitoring in treating to target. Therap Adv Gastroenterol 2017;10:453-63. [PMID: 28567115 DOI: 10.1177/1756283X17698089] [Cited by in Crossref: 4] [Article Influence: 1.0] [Reference Citation Analysis]
21 Ding NS, Hart A, De Cruz P. Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease - algorithm for practical management. Aliment Pharmacol Ther 2016;43:30-51. [PMID: 26515897 DOI: 10.1111/apt.13445] [Cited by in Crossref: 156] [Cited by in F6Publishing: 136] [Article Influence: 26.0] [Reference Citation Analysis]
22 Alfaro I, Masamunt MC, Planell N, López-García A, Castro J, Gallego M, Barastegui R, Giner A, Vara A, Salas A, Ricart E, Panés J, Ordás I. Endoscopic response to tumor necrosis factor inhibitors predicts long term benefits in Crohn’s disease. World J Gastroenterol 2019; 25(14): 1764-1774 [PMID: 31011260 DOI: 10.3748/wjg.v25.i14.1764] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]